BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. J Cyst Fibros 2007;6:117-23. [PMID: 16829217 DOI: 10.1016/j.jcf.2006.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Konstan MW, Borowitz D, Mayer-Hamblett N, Milla C, Hendeles L, Murray S, Kronmal RA, Casey S, Rose LM, Morgan WJ, Ramsey BW. Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis. Clin Investig (Lond) 2013;3:731-41. [PMID: 25132954 DOI: 10.4155/cli.13.63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
2 Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M; Liprotamase 726 Study Group. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011;10:443-452. [PMID: 21831726 DOI: 10.1016/j.jcf.2011.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
3 Ling SC, Ye W, Leung DH, Navarro OM, Weymann A, Karnsakul W, Freeman AJ, Magee JC, Narkewicz MR. Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease. J Pediatr Gastroenterol Nutr 2019;69:351-7. [PMID: 31436672 DOI: 10.1097/MPG.0000000000002413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mayer-Hamblett N, Kloster M, Ramsey BW, Narkewicz MR, Saiman L, Goss CH. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials 2013;34:232-8. [PMID: 23200843 DOI: 10.1016/j.cct.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
5 De Boeck K, Bulteel V, Tiddens H, Wagner T, Fajac I, Conway S, Dufour F, Smyth AR, Lee T, Sermet I, Kassai B, Elborn S; ECFS-CTN network partners. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J Cyst Fibros 2011;10 Suppl 2:S67-74. [PMID: 21658644 DOI: 10.1016/S1569-1993(11)60010-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
6 Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72. [PMID: 22047557 DOI: 10.1056/NEJMoa1105185] [Cited by in Crossref: 1340] [Cited by in F6Publishing: 568] [Article Influence: 121.8] [Reference Citation Analysis]
7 Accurso FJ. Update in cystic fibrosis 2006. Am J Respir Crit Care Med 2007;175:754-7. [PMID: 17405941 DOI: 10.1164/rccm.200701-160UP] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
8 Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-72. [PMID: 20622033 DOI: 10.1164/rccm.201001-0137OC] [Cited by in Crossref: 188] [Cited by in F6Publishing: 83] [Article Influence: 15.7] [Reference Citation Analysis]
9 Darch SE, McNally A, Harrison F, Corander J, Barr HL, Paszkiewicz K, Holden S, Fogarty A, Crusz SA, Diggle SP. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection. Sci Rep 2015;5:7649. [PMID: 25578031 DOI: 10.1038/srep07649] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 11.6] [Reference Citation Analysis]
10 Goss CH, Mayer-hamblett N, Williams J, Ramsey BW. The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network. Children's Health Care 2008;37:5-20. [DOI: 10.1080/02739610701766859] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Pittman JE, Khan U, Laguna TA, Heltshe S, Goss CH, Sanders DB. Rates of adverse and serious adverse events in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)00048-5. [PMID: 33745860 DOI: 10.1016/j.jcf.2021.02.013] [Reference Citation Analysis]